NICE confirms advanced breast cancer drug is too expensive for NHS

BMJ. 2014 Aug 7:349:g5078. doi: 10.1136/bmj.g5078.
No abstract available

Publication types

  • News

MeSH terms

  • Ado-Trastuzumab Emtansine
  • Antibodies, Monoclonal, Humanized / economics*
  • Antineoplastic Agents / economics*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Cost-Benefit Analysis*
  • England
  • Female
  • Humans
  • Maytansine / analogs & derivatives*
  • Maytansine / economics
  • State Medicine / economics*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Maytansine
  • Trastuzumab
  • Ado-Trastuzumab Emtansine